<DOC>
	<DOCNO>NCT00973115</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety morning versus even intake Simvastatin Controlled Release tablet 20mg 8 week patient hyperlipidemia . This study investigate equivalence low-density lipoprotein ( LDL ) cholesterol percent change .</brief_summary>
	<brief_title>Efficacy Safety Morning Versus Evening Intake Simvast Controlled Release ( CR ) Tablet Patients With Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Aged 19 75 Defined fast 100mg/dl≤ LDL cholesterol &lt; 220mg/dl triglyceride level &lt; 400 mg/dl Need drug therapy NCEP ATP III guideline Signed informed consent Has hypersensitivity HMGCoA reductase inhibitor simvastatin Has presence history alcohol abuse drug abuse Active gallbladder disease within 12 month Pancreatitis Hepatic dysfunction ( ALT AST level &gt; 2XUNL ) HbA1c≥ 9 % type 2 diabetes mellitus patient SBP &lt; 90mmHg &gt; 160mmHg DBP &lt; 50mmHg &gt; 100mmHg Myocardial infarction revascularization procedure within 6 month Has significant cardiovascular disease Malignant tumor within 5years Has fibromyalgia , myopathy , rhabdomyolysis acute myalgia Uric acid level &gt; 9 mg/dl Thyroid stimulate hormone ≥ 2XUNL Active peptic ulcer disease CPK level &gt; 3XUNL creatinine level &gt; 2 mg/dl Negative pregnancy test woman childbearing age agreement use contraception study Had participate clinical trial within 4 week Need systemic administration corticosteroid intermittently</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>